|MPhA Pharmacy Advocacy Research Fund|
We are reaching out with important news related to MPhA’s ongoing work to support its members on reimbursement-related issues. We are excited to announce our Legislative Quarterback, lobbyist Buck Humphrey, has been retained by MPhA to research the possibilities of introducing patient fair practices legislation that would address a number of issues. An informal coalition, including medicine representatives, have been quietly talking over the past several months and is now visiting with MN legislators & regulators about patient access issues, gag clauses, co-pay and other clawbacks, transparency, prescription delivery restrictions and other important issues that many are extremely concerned about. This issues negatively impact patients and pharmacists providing care to them.
As you may know, Buck is also retained under contract to proactively promote the advocacy agenda of the Pharmacy Advocacy Task Force (PATF, formerly known as the Pharmacy Practice Act Joint Task Force) through the 2018 Legislative Session. MPhA shares that financial lobbying commitment equally with our colleagues at the Minnesota Society of Health Systems Pharmacy (MSHP) and the $19,000 we pay is raised exclusively from donations.
Now, we are raising funds from members and non-members alike exclusively for MPhA to pay Hill Strategies to work on reimbursement issues outside of those on the PATF agenda.
We have had members generously donate funds ($8,000) so that we can lay the strategic groundwork for the 2018 legislative session and beyond and we have important partners. Now we need to raise the additional funds to work this issue during 2018 and beyond. We need to raise a minimum of $15,000 to do so.
We are calling on you to get behind our efforts, to actively participate in the education of our citizens and legislators and to contribute financially to these efforts.
We have not had financial resources for pharmacy representation at the Minnesota Capitol for several years. We have made noticeable gains by having a lobbyist working the PATF agenda and it is clear that we need to devote lobbying efforts to the patient fair practices effort. We can only accomplish this with your contributions to the MPhA Pharmacy Advocacy Research Fund. With Buck’s leadership and coalition partners, we are optimistic that we can accomplish strides in this arena.
Although advocacy work has always been important to us, we do not have the resources in our operating budget and we must raise these additional funds to devote specifically to these contracted advocacy efforts. We pledge that funds raised will be specifically allocated to MPhA-specific efforts around these issues.